Phase 2 Trial Oral Enzastaurin in Prostate Cancer Patients Who Have Rising PSA (1) During Hormonal Manipulation and (2) After First-Line Cytotoxic Chemotherapy
The purpose is to see how quickly two different types of prostate cancer patients respond when taking enzastaurin. Cohort 1 - asymptomatic patients with androgen-independent PSA-progressive disease with or without clinical or radiographic evidence of metastatic disease. Cohort 2 - patients with androgen-independent metastatic prostate cancer (documented bone or soft tissue metastases) with rising PSA, clinical, radiographic disease progression following one prior docetaxel-based regimen
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : Enzastaurin
Phase: Phase 2
Ages Eligible For Study:
- You are expected to be alive in the 12 weeks. - You are at least 18 years old. - You live close enough to the doctor's office to attend all of your required visits. - You have not been treated with chemotherapy for your prostate cancer (cohort 1). - You have had one prior docetaxel-based chemotherapy regimen (cohort 2). - You have evidence of metastatic prostate cancer with bone or soft tissue disease (cohort 2). - Your organs must be functioning properly.